Myelofibrosis classification: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 17: Line 17:


===Secondary Myelofibrosis===
===Secondary Myelofibrosis===
*Myelofibrosis can be secondary to mulpltiple primary conditons such as:
*Myelofibrosis can be secondary to multiple primary conditions such as:
:*Malignancies and hematologic disorders (Hodgkin lymphoma, non-Hodgkin lymphoma, essential thrombocythemia, polycythemia vera, multiple myeloma, and malignancies with metastases to the bone)
:*Malignancies and hematologic disorders (Hodgkin lymphoma, non-Hodgkin lymphoma, essential thrombocythemia, polycythemia vera, multiple myeloma, and malignancies with metastases to the bone)<ref name="pmid23787440">{{cite journal |vauthors=Boiocchi L, Mathew S, Gianelli U, Iurlo A, Radice T, Barouk-Fox S, Knowles DM, Orazi A |title=Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage |journal=Mod. Pathol. |volume=26 |issue=12 |pages=1577–85 |date=December 2013 |pmid=23787440 |doi=10.1038/modpathol.2013.109 |url=}}</ref><ref name="pmid28781273">{{cite journal |vauthors=Sakatoku K, Takeoka Y, Araki T, Miura A, Fujitani Y, Yamamura R, Miyagi Y, Senzaki H, Ohta K |title=Lymphocyte-depleted classical Hodgkin lymphoma accompanied by myelofibrosis |language=Japanese |journal=Rinsho Ketsueki |volume=58 |issue=7 |pages=772–775 |date=2017 |pmid=28781273 |doi=10.11406/rinketsu.58.772 |url=}}</ref><ref name="pmid26622707">{{cite journal |vauthors=Fu R, Yu H, Wu YH, Liu H, Shao ZH |title=Hodgkin's lymphoma associated with myelofibrosis: A case report |journal=Oncol Lett |volume=10 |issue=3 |pages=1551–1554 |date=September 2015 |pmid=26622707 |pmc=4533276 |doi=10.3892/ol.2015.3438 |url=}}</ref><ref name="pmid26117015">{{cite journal |vauthors=Liu YL, Wang WJ, Wang XN |title=[Pathological Characteristics of Bone Marrow in Non-Hodgkin's Lymphoma Patients with Secondary Myelofibrosis and Their Relationship with Prognosis] |language=Chinese |journal=Zhongguo Shi Yan Xue Ye Xue Za Zhi |volume=23 |issue=3 |pages=674–8 |date=June 2015 |pmid=26117015 |doi=10.7534/j.issn.1009-2137.2015.03.014 |url=}}</ref><ref name="pmid28239786">{{cite journal |vauthors=Dolgikh TY, Domnikova NP, Tornuev YV, Vinogradova EV, Krinitsyna YM |title=Incidence of Myelofibrosis in Chronic Myeloid Leukemia, Multiple Myeloma, and Chronic Lymphoid Leukemia during Various Phases of Diseases |journal=Bull. Exp. Biol. Med. |volume=162 |issue=4 |pages=483–487 |date=February 2017 |pmid=28239786 |doi=10.1007/s10517-017-3645-x |url=}}</ref><ref name="pmid28823272">{{cite journal |vauthors=Zhao J, Ma L, Guan JH |title=[Pathological Characteristics of Bone Marrow in Multiple Myeloma Patients with Secondary Myelofibrosis and Their Relationship with Prognosis] |language=Chinese |journal=Zhongguo Shi Yan Xue Ye Xue Za Zhi |volume=25 |issue=4 |pages=1080–1085 |date=August 2017 |pmid=28823272 |doi=10.7534/j.issn.1009-2137.2017.04.021 |url=}}</ref><ref name="pmid28561069">{{cite journal |vauthors=Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM |title=A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis |journal=Leukemia |volume=31 |issue=12 |pages=2726–2731 |date=December 2017 |pmid=28561069 |doi=10.1038/leu.2017.169 |url=}}</ref><ref name="pmid28601551">{{cite journal |vauthors=Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S |title=Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis |journal=Leuk. Res. |volume=59 |issue= |pages=110–116 |date=August 2017 |pmid=28601551 |pmc=5573611 |doi=10.1016/j.leukres.2017.06.001 |url=}}</ref><ref name="pmid14302719">{{cite journal |vauthors=MARKAND ON |title=SECONDARY MARBLE BONE DISEASE: GENERALISED OSTEOSCLEROSIS AND MYELOFIBROSIS IN CARCINOMA OF PROSTATE WITH A CASE REPORT |journal=J Assoc Physicians India |volume=13 |issue= |pages=349–55 |date=May 1965 |pmid=14302719 |doi= |url=}}</ref><ref name="pmid12897334">{{cite journal |vauthors=Chang JC, Naqvi T |title=Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer |journal=Oncologist |volume=8 |issue=4 |pages=375–80 |date=2003 |pmid=12897334 |doi= |url=}}</ref><ref name="pmid5458299">{{cite journal |vauthors=Hiwada K, Sera Y, Nishimura M |title=[Autopsy case of secondary myelofibrosis due to bone marrow metastasis of stomach cancer] |language=Japanese |journal=Iryo |volume=24 |issue=7 |pages=585–90 |date=July 1970 |pmid=5458299 |doi= |url=}}</ref>
:* Toxins (Benzene, thorium dioxide, and x- or γ-radiation)
:* Toxins (Benzene, thorium dioxide, nitrosurea, and x- or γ-radiation)<ref name="pmid28715625">{{cite journal |vauthors=Bausà R, Navarro L, Cortès-Franch I |title=[Myelofibrosis in a benzene-exposed cleaning worker] |language=Spanish; Castilian |journal=Arch Prev Riesgos Labor |volume=20 |issue=3 |pages=167–169 |date=2017 |pmid=28715625 |doi=10.12961/aprl.2017.20.3.03 |url=}}</ref><ref name="pmid3789571">{{cite journal |vauthors=Hu H |title=Benzene-associated myelofibrosis |journal=Ann. Intern. Med. |volume=106 |issue=1 |pages=171–2 |date=January 1987 |pmid=3789571 |doi= |url=}}</ref><ref name="pmid7703476">{{cite journal |vauthors=Tondel M, Persson B, Carstensen J |title=Myelofibrosis and benzene exposure |journal=Occup Med (Lond) |volume=45 |issue=1 |pages=51–2 |date=February 1995 |pmid=7703476 |doi= |url=}}</ref><ref name="pmid7695889">{{cite journal |vauthors=Visfeldt J, Andersson M |title=Pathoanatomical aspects of malignant haematological disorders among Danish patients exposed to thorium dioxide |journal=APMIS |volume=103 |issue=1 |pages=29–36 |date=January 1995 |pmid=7695889 |doi= |url=}}</ref><ref name="pmid302634">{{cite journal |vauthors=Brandt L, Emanuelsson H, Mitelman F, Stenstam M, Söderström N |title=Pronounced deficiency in T-cells and lymphocyte chromosomal aberrations in a patient with sarcoidosis, myelofibrosis and acute leukaemia following thorotrast angiography |journal=Acta Med Scand |volume=201 |issue=5 |pages=487–9 |date=1977 |pmid=302634 |doi= |url=}}</ref><ref name="pmid7393792">{{cite journal |vauthors=Arnold AG, Oelbaum MH |title=Thorotrast administration followed by myelofibrosis |journal=Postgrad Med J |volume=56 |issue=652 |pages=124–7 |date=February 1980 |pmid=7393792 |pmc=2425512 |doi= |url=}}</ref><ref name="pmid748384">{{cite journal |vauthors=Jennings RC, Priestley SE |title=Haemangioendothelioma (Kupffer cell angiosarcoma), myelofibrosis, splenic atrophy, and myeloma paraproteinaemia after parenteral thorotrast administration |journal=J. Clin. Pathol. |volume=31 |issue=12 |pages=1125–32 |date=December 1978 |pmid=748384 |pmc=1145517 |doi= |url=}}</ref><ref name="pmid3742462">{{cite journal |vauthors=McKenney SA, Fehir KM |title=Myelofibrosis following treatment with a nitrosourea for malignant glioma |journal=Cancer |volume=58 |issue=7 |pages=1426–7 |date=October 1986 |pmid=3742462 |doi= |url=}}</ref>
:*Infections (Osteomyelitis, tuberculosis [TB])
:*Infections (tuberculosis [TB], HIV infection, and dengue fever)<ref name="pmid25016180">{{cite journal |vauthors=Qing X, Sun N, Yeh J, Yue C, Cai J |title=Dengue fever and bone marrow myelofibrosis |journal=Exp. Mol. Pathol. |volume=97 |issue=2 |pages=208–10 |date=October 2014 |pmid=25016180 |doi=10.1016/j.yexmp.2014.07.004 |url=}}</ref><ref name="pmid21894472">{{cite journal |vauthors=Lee AC, Fong CM |title=Autoimmune myelofibrosis as the first manifestation of human immunodeficiency virus infection in an infant |journal=Ann. Hematol. |volume=91 |issue=5 |pages=809–810 |date=May 2012 |pmid=21894472 |doi=10.1007/s00277-011-1329-6 |url=}}</ref><ref name="pmid9176580">{{cite journal |vauthors=Hashim MS, Kordofani AY, el Dabi MA |title=Tuberculosis and myelofibrosis in children: a report |journal=Ann Trop Paediatr |volume=17 |issue=1 |pages=61–5 |date=March 1997 |pmid=9176580 |doi= |url=}}</ref><ref name="pmid12032901">{{cite journal |vauthors=Viallard JF, Parrens M, Boiron JM, Texier J, Mercie P, Pellegrin JL |title=Reversible myelofibrosis induced by tuberculosis |journal=Clin. Infect. Dis. |volume=34 |issue=12 |pages=1641–3 |date=June 2002 |pmid=12032901 |doi=10.1086/340524 |url=}}</ref>
:*Autoimmune diseases (systemic lupus erythematosus [SLE], multiple sclerosis [MS])
:*Autoimmune diseases (systemic lupus erythematosus [SLE], multiple sclerosis [MS], and juvenile idiopathic arthritis)<ref name="pmid27102067">{{cite journal |vauthors=Jain N, Sinha R, Sengupta J, Chakrabartty J |title=A rare case of myelofibrosis secondary to juvenile idiopathic arthritis |journal=Br. J. Haematol. |volume=173 |issue=6 |pages=819 |date=June 2016 |pmid=27102067 |doi=10.1111/bjh.14106 |url=}}</ref><ref name="pmid28293461">{{cite journal |vauthors=Cansu DÜ, Teke HÜ, Korkmaz C |title=A rare cause of cytopenia in a patient with systemic lupus erythematosus: Autoimmune myelofibrosis |journal=Eur J Rheumatol |volume=4 |issue=1 |pages=76–78 |date=March 2017 |pmid=28293461 |pmc=5335895 |doi=10.5152/eurjrheum.2016.011 |url=}}</ref><ref name="pmid24371783">{{cite journal |vauthors=Thorsteinsdottir S, Bjerrum OW, Hasselbalch HC |title=Myeloproliferative neoplasms in five multiple sclerosis patients |journal=Leuk Res Rep |volume=2 |issue=2 |pages=61–3 |date=2013 |pmid=24371783 |pmc=3850374 |doi=10.1016/j.lrr.2013.06.004 |url=}}</ref>


==References==
==References==

Revision as of 16:54, 9 November 2018

Myelofibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myelofibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myelofibrosis classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myelofibrosis classification

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myelofibrosis classification

CDC on Myelofibrosis classification

Myelofibrosis classification in the news

Blogs on Myelofibrosis classification

Directions to Hospitals Treating Myelofibrosis

Risk calculators and risk factors for Myelofibrosis classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2], Sujit Routray, M.D. [3]

Overview

Myelofibrosis is subclassified into primary and secondary types with the primary type being the more common and a high proportion of the cases resulting from mutations in the Janus kinase 2 (JAK2) gene. It can be secondary to a variety of malignant, non-malignant, and hematologic conditions. It can also be secondary to infections, toxins, and autoimmune diseases.

Classification

  • Myelofibrosis is divided into two types:
  • Primary
  • Secondary

Primary Myelofibrosis

  • The primary type, characterized by stem cell-derived clonal myeloproliferation, is often associated with mutations of the thrombopoietin receptor gene (MPL), the calreticulin (CALR) gene, or Janus kinase 2 (JAK2) gene with 90% of the patients carrying one of these mutations and the rest 10% are categorized as "triple-negative".[1][2]
  • The 2016 World Health Organization (WHO) revised classification of myeloproliferative neoplasms (MPNs) defines 2 stages of primary myelofibrosis (PMF):
  • Prefibrotic/early (pre-primary myelofibrosis) phase, characterized by granulocytic/megakaryocytic proliferation and lack of reticulin bone marrow fibrosis.[3][4]
  • Overtly fibrotic (overt primary myelofibrosis) phase, characterized by bone marrow fibrosis, pancytopenia, higher blast count, extramedullary hematopoiesis, and unfavorable karyotype with a significantly shortened median survival.[3]

Secondary Myelofibrosis

  • Myelofibrosis can be secondary to multiple primary conditions such as:
  • Malignancies and hematologic disorders (Hodgkin lymphoma, non-Hodgkin lymphoma, essential thrombocythemia, polycythemia vera, multiple myeloma, and malignancies with metastases to the bone)[5][6][7][8][9][10][11][12][13][14][15]
  • Toxins (Benzene, thorium dioxide, nitrosurea, and x- or γ-radiation)[16][17][18][19][20][21][22][23]
  • Infections (tuberculosis [TB], HIV infection, and dengue fever)[24][25][26][27]
  • Autoimmune diseases (systemic lupus erythematosus [SLE], multiple sclerosis [MS], and juvenile idiopathic arthritis)[28][29][30]

References

  1. ↑ Tefferi A (December 2016). "Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management". Am. J. Hematol. 91 (12): 1262–1271. doi:10.1002/ajh.24592. PMID 27870387.
  2. ↑ Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A (February 2018). "The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion". Blood Cancer J. 8 (2): 15. doi:10.1038/s41408-018-0054-y. PMC 5807384. PMID 29426921.
  3. ↑ 3.0 3.1 Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, Maffioli M, Fanelli T, Pancrazzi A, Pietra D, Salmoiraghi S, Mannarelli C, Franci A, Paoli C, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM (June 2017). "Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis". Blood. 129 (24): 3227–3236. doi:10.1182/blood-2017-01-761999. PMID 28351937.
  4. ↑ Rumi E, Cazzola M (February 2017). "Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms". Blood. 129 (6): 680–692. doi:10.1182/blood-2016-10-695957. PMC 5335805. PMID 28028026.
  5. ↑ Boiocchi L, Mathew S, Gianelli U, Iurlo A, Radice T, Barouk-Fox S, Knowles DM, Orazi A (December 2013). "Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage". Mod. Pathol. 26 (12): 1577–85. doi:10.1038/modpathol.2013.109. PMID 23787440.
  6. ↑ Sakatoku K, Takeoka Y, Araki T, Miura A, Fujitani Y, Yamamura R, Miyagi Y, Senzaki H, Ohta K (2017). "Lymphocyte-depleted classical Hodgkin lymphoma accompanied by myelofibrosis". Rinsho Ketsueki (in Japanese). 58 (7): 772–775. doi:10.11406/rinketsu.58.772. PMID 28781273.
  7. ↑ Fu R, Yu H, Wu YH, Liu H, Shao ZH (September 2015). "Hodgkin's lymphoma associated with myelofibrosis: A case report". Oncol Lett. 10 (3): 1551–1554. doi:10.3892/ol.2015.3438. PMC 4533276. PMID 26622707.
  8. ↑ Liu YL, Wang WJ, Wang XN (June 2015). "[Pathological Characteristics of Bone Marrow in Non-Hodgkin's Lymphoma Patients with Secondary Myelofibrosis and Their Relationship with Prognosis]". Zhongguo Shi Yan Xue Ye Xue Za Zhi (in Chinese). 23 (3): 674–8. doi:10.7534/j.issn.1009-2137.2015.03.014. PMID 26117015.
  9. ↑ Dolgikh TY, Domnikova NP, Tornuev YV, Vinogradova EV, Krinitsyna YM (February 2017). "Incidence of Myelofibrosis in Chronic Myeloid Leukemia, Multiple Myeloma, and Chronic Lymphoid Leukemia during Various Phases of Diseases". Bull. Exp. Biol. Med. 162 (4): 483–487. doi:10.1007/s10517-017-3645-x. PMID 28239786.
  10. ↑ Zhao J, Ma L, Guan JH (August 2017). "[Pathological Characteristics of Bone Marrow in Multiple Myeloma Patients with Secondary Myelofibrosis and Their Relationship with Prognosis]". Zhongguo Shi Yan Xue Ye Xue Za Zhi (in Chinese). 25 (4): 1080–1085. doi:10.7534/j.issn.1009-2137.2017.04.021. PMID 28823272.
  11. ↑ Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM (December 2017). "A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis". Leukemia. 31 (12): 2726–2731. doi:10.1038/leu.2017.169. PMID 28561069.
  12. ↑ Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S (August 2017). "Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis". Leuk. Res. 59: 110–116. doi:10.1016/j.leukres.2017.06.001. PMC 5573611. PMID 28601551.
  13. ↑ MARKAND ON (May 1965). "SECONDARY MARBLE BONE DISEASE: GENERALISED OSTEOSCLEROSIS AND MYELOFIBROSIS IN CARCINOMA OF PROSTATE WITH A CASE REPORT". J Assoc Physicians India. 13: 349–55. PMID 14302719.
  14. ↑ Chang JC, Naqvi T (2003). "Thrombotic thrombocytopenic purpura associated with bone marrow metastasis and secondary myelofibrosis in cancer". Oncologist. 8 (4): 375–80. PMID 12897334.
  15. ↑ Hiwada K, Sera Y, Nishimura M (July 1970). "[Autopsy case of secondary myelofibrosis due to bone marrow metastasis of stomach cancer]". Iryo (in Japanese). 24 (7): 585–90. PMID 5458299.
  16. ↑ Bausà R, Navarro L, Cortès-Franch I (2017). "[Myelofibrosis in a benzene-exposed cleaning worker]". Arch Prev Riesgos Labor (in Spanish; Castilian). 20 (3): 167–169. doi:10.12961/aprl.2017.20.3.03. PMID 28715625.
  17. ↑ Hu H (January 1987). "Benzene-associated myelofibrosis". Ann. Intern. Med. 106 (1): 171–2. PMID 3789571.
  18. ↑ Tondel M, Persson B, Carstensen J (February 1995). "Myelofibrosis and benzene exposure". Occup Med (Lond). 45 (1): 51–2. PMID 7703476.
  19. ↑ Visfeldt J, Andersson M (January 1995). "Pathoanatomical aspects of malignant haematological disorders among Danish patients exposed to thorium dioxide". APMIS. 103 (1): 29–36. PMID 7695889.
  20. ↑ Brandt L, Emanuelsson H, Mitelman F, Stenstam M, Söderström N (1977). "Pronounced deficiency in T-cells and lymphocyte chromosomal aberrations in a patient with sarcoidosis, myelofibrosis and acute leukaemia following thorotrast angiography". Acta Med Scand. 201 (5): 487–9. PMID 302634.
  21. ↑ Arnold AG, Oelbaum MH (February 1980). "Thorotrast administration followed by myelofibrosis". Postgrad Med J. 56 (652): 124–7. PMC 2425512. PMID 7393792.
  22. ↑ Jennings RC, Priestley SE (December 1978). "Haemangioendothelioma (Kupffer cell angiosarcoma), myelofibrosis, splenic atrophy, and myeloma paraproteinaemia after parenteral thorotrast administration". J. Clin. Pathol. 31 (12): 1125–32. PMC 1145517. PMID 748384.
  23. ↑ McKenney SA, Fehir KM (October 1986). "Myelofibrosis following treatment with a nitrosourea for malignant glioma". Cancer. 58 (7): 1426–7. PMID 3742462.
  24. ↑ Qing X, Sun N, Yeh J, Yue C, Cai J (October 2014). "Dengue fever and bone marrow myelofibrosis". Exp. Mol. Pathol. 97 (2): 208–10. doi:10.1016/j.yexmp.2014.07.004. PMID 25016180.
  25. ↑ Lee AC, Fong CM (May 2012). "Autoimmune myelofibrosis as the first manifestation of human immunodeficiency virus infection in an infant". Ann. Hematol. 91 (5): 809–810. doi:10.1007/s00277-011-1329-6. PMID 21894472.
  26. ↑ Hashim MS, Kordofani AY, el Dabi MA (March 1997). "Tuberculosis and myelofibrosis in children: a report". Ann Trop Paediatr. 17 (1): 61–5. PMID 9176580.
  27. ↑ Viallard JF, Parrens M, Boiron JM, Texier J, Mercie P, Pellegrin JL (June 2002). "Reversible myelofibrosis induced by tuberculosis". Clin. Infect. Dis. 34 (12): 1641–3. doi:10.1086/340524. PMID 12032901.
  28. ↑ Jain N, Sinha R, Sengupta J, Chakrabartty J (June 2016). "A rare case of myelofibrosis secondary to juvenile idiopathic arthritis". Br. J. Haematol. 173 (6): 819. doi:10.1111/bjh.14106. PMID 27102067.
  29. ↑ Cansu DÜ, Teke HÜ, Korkmaz C (March 2017). "A rare cause of cytopenia in a patient with systemic lupus erythematosus: Autoimmune myelofibrosis". Eur J Rheumatol. 4 (1): 76–78. doi:10.5152/eurjrheum.2016.011. PMC 5335895. PMID 28293461.
  30. ↑ Thorsteinsdottir S, Bjerrum OW, Hasselbalch HC (2013). "Myeloproliferative neoplasms in five multiple sclerosis patients". Leuk Res Rep. 2 (2): 61–3. doi:10.1016/j.lrr.2013.06.004. PMC 3850374. PMID 24371783.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Myelofibrosis_classification&oldid=1502633"